Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gisadenafil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A known ✓ | O76074 | 20/20 | 0.89 |
| ▸ | PDE6C | P51160 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gisadenafil SCHEMBL29379724 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| Gisadenafil SCHEMBL120995 | 0.94 | PDE5A (1.00) | PDE5APDE6C | |
| Gisadenafil SCHEMBL3585141 | 0.91 | PDE5A (0.87) | PDE5APDE6C | |
| SCHEMBL3579657 | 0.90 | PDE5A (0.91) | PDE5APDE6C | |
| SCHEMBL3576608 | 0.90 | PDE5A (1.00) | PDE5APDE6C | |
| Gisadenafil SCHEMBL3583099 | 0.90 | PDE5A (0.88) | PDE5APDE6C | |
| Gisadenafil SCHEMBL29478482 | 0.90 | PDE5A (0.88) | PDE5APDE6C | |
| SCHEMBL4559199 | 0.90 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL6767921 | 0.90 | PDE5A (0.90) | PDE5APDE6C | |
| SCHEMBL3584023 | 0.90 | PDE5A (1.00) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305314-B1 | CRYSTALLINE THERAPEUTIC AGENT | PFIZER LTD (GB) | 2005-01-12 | — | — | EP | disclosed |
| EP-1305314-A1 | CRYSTALLINE THERAPEUTIC AGENT | Pfizer Limited (GB) | 2003-05-02 | — | — | EP | disclosed |
| US-6420557-B1 | FOR THERAPY OF MALE ERECTILE DYSFUNCTION | PFIZER INC. | 2002-07-16 | — | — | US | disclosed |
| US-20020040140-A1 | For therapy of male erectile dysfunction | PFIZER INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002010171-A1 | CRYSTALLINE THERAPEUTIC AGENT | PFIZER LIMITED (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040140-A1 | For therapy of male erectile dysfunction | PDE3A, PDE5A, PDE3B | PDE5A 2/4885PDE6C 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.